|
2007
September - SciTech was selected to participate in the 2007-2008 HIH SBIR Commercialization Assistance Program (CAP), a customized and individualized commercial market-based program for SBIR Phase II grantees.
August - SciTech submits SBIR grant application entitled "The Prophylactic Effects of the Calcium Ionophores on Wound Healing in Diabetic and Senescent Skin".
SciTech Development listed in Crain’s Detroit Business 2007 Book of Lists and Detroit Yearbook: University Research
January - CUPSI completes release of all pilot scale batches manufactured.
February - SRI and SciTech demonstrate application of external strain to the elastomeric substrate Electroactive Polymer Artificial Muscle (EPAM) actuator.
March - SciTech files patent application titled “Liposomal Nanoparticles and Other Formulations of Fenretinide for Use in Therapy and Drug Delivery”.
-SciTech is accepted into FrontLine Accelerator for Science and Technology (FAST), a process designed by TechTown for customizing a growth plan for technology start-ups.
April - CUPSI completes sterility and stability testing for all pilot scale batches.
2006
SciTech Defines the IV Formulation for Fenretinide IV Product
-
April - SciTech Defines the IV formulation for Fenretinide IV product.
-
August- SciTech and CUPSI successfully complete tech transfer process to CUPSI by producing a 50mL batch at CUPSI using an approved batch record.
Crain’s Detroit Business published SciTech Development among the ten companies that derived their technology from local universities and showed great potential to commercialize their products.
-
September - SciTech and SRI complete testing of all candidate elastomers for attachment of cardiac cells and determine the most suitable elastomeric substrate.
-
November- CUPSI completes manufacturing of pilot scale batches.
SciTech relocates to TechTown, a research and technology park encompassing 12 city blocks and acres in Detroit.
2005
-
November -
Successful transfer of live cardiac cells through mail from Stanford Research
Institute (SRI) to our Michigan laboratory. These heart cells have since grown
and divided while also reestablishing cardiac rhythm.
-
Campbell commenced work on scale-up formulation
for IV Retiniod technology.
-
January 1 - Breast cancer detection machine
modified for simultaneous firing of multiple transducer elements. Successful demonstrations of focusing the
ultrasound energy through Time-Reversal Technology. (HIFU)
2004
-
November 15 - Struck licensing agreement with Wayne State University in relation to "Parenteral
Formulations for Synthetic Retinoids" grant.
-
September 24- Awarded $239,947 from NIH for STTR
Grant entitled "In Vitro Cardiac Device for Assessing Proarrhythmic Risk".
-
September 9 - Research and Product Development
Agreement struck between Ferndale Laboratories, Inc. and SciTech in conjunction
with "Non-Irratating Topical Products for Difficult
Squamous Carcinomas of the Skin." Ferndale is engaged in the development,
manufacturing, and commercializing of cosmetic and pharmaceutical products.
Ferndale and SciTech will co-develop a product for topical drug treatment of BCC
and SCC, and/or other non-melanoma skin cancers.
-
September - Phantom breast tests for "Clinical
Breast Ultrasound Tomography" grant met resolution, contrast, and locations
accuracy targets. 10 patients from WCBCC affirmed the phantom test results as
well as ability to differentiate tissue types. A early system has also been
established in conjunction with these findings for scoring cancer results.
-
May 1 - SciTech and Wayne State University (WSU)
entered into an agreement regarding WSU scientists conducting studies for the IV Retinoids grant.
-
April 1 -
Struck an Intellectual Property Agreement, for the "Parenteral
Formulations of Synthetic Retinoids" grant, with Wayne State University.
-
April 1 - Awarded $144,683 from NIH for Phase I
SBIR Grant entitled "Dynamic Focusing for Non-Invasive
Treatments". HIFU technology is applied through the use of a platform breast detection technology. Analogic Corporations begins in joint-development as stated in July 17, 2003
agreement. University of California at Santa Barbara also included in
joint-research as designated in "Period of Performance" agreement.
-
April - Groupvelocity LLC, Alexander J. Walt
Comprehensive Breast Cancer Clinic (WCBCC) at Karmanos Cancer Institute (KCI),
and Analogic Corporations begin
collaborative work with SciTech on "Clinical Breast
Ultrasound Tomography" grant. Groupvelocity, headquartered in Albuquerque,
NM, specializes in providing technical and scientific services beyond the scope
of conventional consulting. WCBCC, located within the Detroit Medical Center,
has become a resource to thousands of women in the metro-Detroit area for breast
cancer screening and diagnosis. Analogic is a leading designer and manufacturer
of advanced systems and subsystems and are known for advancing Computed
Tomography, Digital Radiography, Ultrasound, Magnetic Resonance Imaging, Patient
Monitoring, Cardiovascular Information Management, and Embedded Multiprocessing
applications.
-
April 1 -
Awarded $140,800 from NIH for Phase I SBIR Grant entitled "Clinical
Breast Ultrasound Tomography".
2003
-
December - Entered in joint-research agreement
with Stanford Research Institute.
-
December 1- Awarded $1,509,206 from NIH for a
Phase II SBIR Grant entitled "Parenteral Formulations
for Synthetic Retinoids".
-
December - Campbell Pharmaceutical Sciences
Institute (CUPSI) and SciTech reach collaborative-research agreement concerning
the development of IV Retinoids Therapy. Campbell
is a Pharmacy Research Facility designed to enhance the development of
innovative academic and research programs.
-
October 1 - Licensing Agreement struck with
Wayne State University concerning the use of a Vitamin
A analog for the development of a topical product to treat Squamous
Carcinoma.
-
August 10 - An Option Agreement for the
acquisition of certain technology/intellectual property needed for development
of a topical product to treat Squamous Cell Carcinoma has been struck with Wayne State University.
2001
-
September - SciTech was awarded a Phase I
Small Business Innovative Research (SBIR) grant to develop stereoisomers of
arylproprionic acids as cancer chemotherapeutic agents. The preferred
enantiomeric configuration of these compounds is unstable in vivo, and the Phase
I grant explores the feasibility of several chemical approaches to
stabilizing the more active configurations. [1R43-CA090088]
-
September 17 - Entered in Intellectual Property
Disposition concerning the SBIR "Parenteral
Formulations for Synthetic Retinoids" Grant
-
August - SciTech
was awarded a
Phase I SBIR grant to develop parenteral formulations of poorly-soluble neutral
retinoids that are inactive after oral administration because of very low
bioavailability. Intravenous (IV) administration by-passes the limited
systemic exposure from oral dosing and potentially achieve levels required to
induce apoptosis in human tumor cells via RAR/RXR-independent pathways.
-
July 7 - SciTech and University of the Pacific
in Stockton, CA, a non-profit university organized and existing under the laws
of the State of California, enter into a Research Services Agreement relating to
the evaluation, formulation, and administration of certain chemical compounds.
|
